234 related articles for article (PubMed ID: 30190486)
21. Can EGFR mutations in plasma or serum be predictive markers of non-small-cell lung cancer? A meta-analysis.
Wu Y; Liu H; Shi X; Song Y
Lung Cancer; 2015 Jun; 88(3):246-53. PubMed ID: 25837799
[TBL] [Abstract][Full Text] [Related]
22. Importance of repeat tissue biopsy and tissue-based epidermal growth factor receptor T790M testing in progressed nonsmall cell lung carcinoma patients upon negative plasma genotyping for selection of third-generation tyrosine kinase inhibitor therapy: A case study.
Mistry R; Patil A
Indian J Cancer; 2017 Dec; 54(Supplement):S65-S66. PubMed ID: 29292710
[TBL] [Abstract][Full Text] [Related]
23. Is it feasible to detect epidermal growth factor receptor mutations in circulating tumor cells in nonsmall cell lung cancer?: A meta-analysis.
Liu Y; Xing Z; Zhan P; Liu H; Ye W; Lv T; Song Y
Medicine (Baltimore); 2016 Nov; 95(47):e5115. PubMed ID: 27893656
[TBL] [Abstract][Full Text] [Related]
24. EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial.
Fassunke J; Ihle MA; Lenze D; Lehmann A; Hummel M; Vollbrecht C; Penzel R; Volckmar AL; Stenzinger A; Endris V; Jung A; Lehmann U; Zeugner S; Baretton G; Kreipe H; Schirmacher P; Kirchner T; Dietel M; Büttner R; Merkelbach-Bruse S
Virchows Arch; 2017 Oct; 471(4):509-520. PubMed ID: 28884371
[TBL] [Abstract][Full Text] [Related]
25. Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS.
Arriola E; Paredes-Lario A; García-Gomez R; Diz-Tain P; Constenla M; García-Girón C; Márquez G; Reck M; López-Vivanco G
Clin Transl Oncol; 2018 Oct; 20(10):1261-1267. PubMed ID: 29623586
[TBL] [Abstract][Full Text] [Related]
26. Comparison of circulating DNA from plasma and urine for EGFR mutations in NSCLC patients.
Zhang H; He B; Cui J; Zhao M; Zhang Z
Cancer Biomark; 2018; 23(3):427-436. PubMed ID: 30223392
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of circulating tumor DNA in localized non-small cell lung cancer: a systematic review and meta-analysis.
Guo RQ; Peng JZ; Sun J; Li YM
Clin Exp Med; 2023 Sep; 23(5):1621-1631. PubMed ID: 36315311
[TBL] [Abstract][Full Text] [Related]
28. 6-Color Crystal Digital PCR
Madic J; Jovelet C; Dehri I; Mallory AC
Methods Mol Biol; 2021; 2279():127-144. PubMed ID: 33683690
[TBL] [Abstract][Full Text] [Related]
29. Circulating tumour DNA in
Cabanero M; Tsao MS
Curr Oncol; 2018 Jun; 25(Suppl 1):S38-S44. PubMed ID: 29910646
[TBL] [Abstract][Full Text] [Related]
30. Using circulating tumor DNA as a novel biomarker to screen and diagnose hepatocellular carcinoma: A systematic review and meta-analysis.
Zhang Z; Chen P; Xie H; Cao P
Cancer Med; 2020 Feb; 9(4):1349-1364. PubMed ID: 31876977
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic and prognostic value of blood samples for KRAS mutation identification in lung cancer: a meta-analysis.
Shen H; Che K; Cong L; Dong W; Zhang T; Liu Q; Du J
Oncotarget; 2017 May; 8(22):36812-36823. PubMed ID: 28415658
[TBL] [Abstract][Full Text] [Related]
32. The Diagnostic Accuracy of Liquid Biopsy in EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis of 40 Studies.
Wang N; Zhang X; Wang F; Zhang M; Sun B; Yin W; Deng S; Wan Y; Lu W
SLAS Technol; 2021 Feb; 26(1):42-54. PubMed ID: 32659150
[TBL] [Abstract][Full Text] [Related]
33. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.
Zheng D; Ye X; Zhang MZ; Sun Y; Wang JY; Ni J; Zhang HP; Zhang L; Luo J; Zhang J; Tang L; Su B; Chen G; Zhu G; Gu Y; Xu JF
Sci Rep; 2016 Feb; 6():20913. PubMed ID: 26867973
[TBL] [Abstract][Full Text] [Related]
34. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
[TBL] [Abstract][Full Text] [Related]
35. Correlation Between Circulating Tumor DNA Levels and Response to Tyrosine Kinase Inhibitors (TKI) Treatment in Non-Small Cell Lung Cancer.
Wei Z; Wang W; Shu Z; Zhou X; Zhang Y
Med Sci Monit; 2017 Jul; 23():3627-3634. PubMed ID: 28742791
[TBL] [Abstract][Full Text] [Related]
36. CRISPR/Cas13a-based supersensitive circulating tumor DNA assay for detecting EGFR mutations in plasma.
Wang L; Wen X; Yang Y; Hu Z; Jiang J; Duan L; Liao X; He Y; Liu Y; Wang J; Liang Z; Zhu X; Liu Q; Liu T; Luo D
Commun Biol; 2024 May; 7(1):657. PubMed ID: 38806596
[TBL] [Abstract][Full Text] [Related]
37. A Rapid and Sensitive Method for Detection of the T790M Mutation of EGFR in Plasma DNA.
Kimura H; Nishikawa S; Koba H; Yoneda T; Sone T; Kasahara K
Adv Exp Med Biol; 2016; 924():171-174. PubMed ID: 27753039
[TBL] [Abstract][Full Text] [Related]
38. Meta-analysis of diagnostic and prognostic value of miR-126 in non-small cell lung cancer.
Sun L; Zhou H; Yang Y; Chen J; Wang Y; She M; Li C
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32329507
[TBL] [Abstract][Full Text] [Related]
39. Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer.
Qian X; Liu J; Sun Y; Wang M; Lei H; Luo G; Liu X; Xiong C; Liu D; Liu J; Tang Y
Oncotarget; 2016 May; 7(20):29154-65. PubMed ID: 27081078
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the Idylla ctEGFR mutation assay to detect EGFR mutations in plasma from patients with non-small cell lung cancers.
Gilson P; Saurel C; Salleron J; Husson M; Demange J; Merlin JL; Harlé A
Sci Rep; 2021 May; 11(1):10470. PubMed ID: 34006948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
